KLRA Kailera Therapeutics, Inc.
Price Chart
Executive Summary
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18.0M in Q1 2025, driven by a $60.7M increase in R&D expenses as the company advances four clinical-stage obesity programs. The filing highlights positive clinical data from partner Hengrui across multiple pipeline candidates and the initiation of the global Phase 3 KaiNETIC program for ribupatide injection, with cash runway into mid-2028 following the $718.8M IPO.
Actionable Insight
KLRA is a pre-revenue clinical-stage biotech with no earnings to beat — the stock will trade on pipeline catalysts, not quarterly P&L. Key near-term catalysts: ADA 2026 presentations (June 5-8), Jefferies Healthcare Conference (June 4), and Phase 2b high-dose ribupatide data in 2027. The $718.8M IPO cash removes near-term financing risk but the widening net loss is expected for a company scaling clinical trials.
Key Facts
- Net loss of $78.9M for Q1 2026 vs $18.0M in Q1 2025
- R&D expenses of $70.9M, up from $10.1M year-over-year
- Cash, cash equivalents and marketable securities of $581.9M as of March 31, 2026
- Closed $718.8M IPO of 44,921,875 shares at $16.00 per share on April 17, 2026
- Initiated global Phase 3 KaiNETIC program for ribupatide injection (GLP-1/GIP dual agonist)
- Positive Phase 3 topline data for KAI-7535 (oral GLP-1) in type 2 diabetes from partner Hengrui
- Positive Phase 1 data for KAI-4729 (GLP-1/GIP/glucagon tri-agonist) showing 16.0% mean weight loss at 12 weeks
- Cash expected to fund operations into mid-2028
Financial Impact
Net loss widened by $60.9M year-over-year; R&D spend increased 7x to $70.9M; no revenue reported (pre-revenue clinical-stage biotech)
Risk Factors
- No approved products or revenue — entirely dependent on clinical trial success
- Competition from established GLP-1 players (Novo Nordisk, Eli Lilly)
- Reliance on partner Hengrui for key clinical data and regulatory submissions in China
- Phase 3 data for lead candidate ribupatide not expected until 2028 — long wait for pivotal readout
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-239362 |
| Document: ck0002096997-20260526.htm | 0001193125-26-239362 |
| Document: 0001193125-26-239362-index-headers.html | 0001193125-26-239362 |
| Document: 0001193125-26-239362-index.html | 0001193125-26-239362 |
| Document: 0001193125-26-239362.txt | 0001193125-26-239362 |
| 8-K Data (Synthetic) | 0001193125-26-239362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
today
|
Press Release
| — | awaiting T+5 | — | — |
|
May 26, 2026
11d ago
|
8-K
| $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $19.37 (−11.59%) |
|
May 26, 2026
11d ago
|
Press Release
| $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $19.37 (−11.59%) |
|
May 13, 2026
24d ago
|
Press Release
| $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $19.37 (−8.24%) |
|
Apr 20, 2026
6w ago
|
8-K
| $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $19.37 (−23.20%) |
|
Apr 20, 2026
6w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.37 (−21.29%) |
|
Apr 20, 2026
6w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.37 (−21.29%) |
|
Apr 20, 2026
6w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.37 (−21.29%) |
|
Apr 17, 2026
7w ago
|
424B4
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.37 (−21.29%) |
|
Apr 17, 2026
7w ago
|
EFFECT
| $26.00 $22.47 | ▼ −13.58% | ▼ −14.13% | $19.37 (−25.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access